Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Research
  • Published:

Treatment satisfaction in patients with erectile dysfunction switching from prostaglandin E1 intracavernosal injection therapy to oral sildenafil citrate

International Journal of Impotence Research volume 15, pages 444–449 (2003)Cite this article

Abstract

Treatment satisfaction, subanalysed by demographic variables, was evaluated in patients switching from successful intracavernosal prostaglandin E1 (PGE1) therapy to oral sildenafil citrate. The validated Erectile Dysfunction Inventory of Treatment Satisfaction questionnaire was administered at the end of PGE1 therapy and after 12 weeks of sildenafil treatment in a multicentre, open-label study. Men with erectile dysfunction (n=176) who were switched from stable PGE1 therapy to sildenafil (25–100 mg) were equally satisfied with onset of action, duration of action, and confidence in ability to engage in sexual activity, but expressed greater overall treatment satisfaction with sildenafil (P<0.01), better ease of use (P<0.001), naturalness of erectile process (P<0.001), and intention to continue treatment (P<0.001). Partners (n=32) were overall more satisfied with sildenafil (P<0.05), and their responses correlated with patient satisfaction (r=0.68). Compared with PGE1 injection, these data suggest that patients may be less likely to discontinue taking sildenafil treatment for their erectile dysfunction.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Jarow JP, Nana-Sinkam P, Sabbagh M, Eskew A . Outcome analysis of goal directed therapy for impotence. J Urol 1996; 155: 1609–1612.

    Article  CAS  PubMed  Google Scholar 

  2. Montague DK et al. Clinical guidelines panel on erectile dysfunction: summary report on the treatment of organic erectile dysfunction. J Urol 1996; 156: 2007–2011.

    Article  CAS  PubMed  Google Scholar 

  3. Porst H et al. Intracavernous Alprostadil Alfadex—an effective and well tolerated treatment for erectile dysfunction. Results of a long-term European study. Int J Impot Res 1998; 10: 225–231.

    Article  CAS  PubMed  Google Scholar 

  4. Montorsi F et al. Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology 1999; 53: 1011–1018.

    Article  CAS  PubMed  Google Scholar 

  5. Goldstein I et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397–1404.

    Article  CAS  PubMed  Google Scholar 

  6. Gupta R, Kirschen J, Barrow RCI, Eid JF . Predictors of success and risk factors for attrition in the use of intracavernosal injection. J Urol 1997; 157: 1681–1686.

    Article  CAS  PubMed  Google Scholar 

  7. Irwin MB, Kata EJ . High attrition rate with intracavernous injection of prostaglandin E1 for impotency. Urology 1994; 43: 84–87.

    Article  CAS  PubMed  Google Scholar 

  8. Rowland DL, Boedhoe HSM, Dohle G, Slob AK . Intracavernosal self-injection therapy in men with erectile dysfunction: satisfaction and attrition in 119 patients. Int J Impot Res 1999; 11: 145–151.

    Article  CAS  PubMed  Google Scholar 

  9. Sexton WJ, Benedict JF, Jarow JP . Comparison of long-term outcomes of penile prostheses and intracavernosal injection therapy. J Urol 1998; 159: 811–815.

    Article  CAS  PubMed  Google Scholar 

  10. Weiss JN, Badlani GH, Ravalli R, Brettschneider N . Reasons for high drop-out rate with self-injection therapy for impotence. Int J Impot Res 1994; 6: 171–174.

    CAS  PubMed  Google Scholar 

  11. Sundaram CP et al. Long-term follow-up of patients receiving injection therapy for erectile dysfunction. Urology 1997; 49: 932–935.

    Article  CAS  PubMed  Google Scholar 

  12. Linet OI, Ogrinc FG . Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med 1996; 334: 873–877.

    Article  CAS  PubMed  Google Scholar 

  13. Carson CC, Burnett AL, Levine LA, Nehra A . The efficacy of sildenafil citrate (Viagra®) in clinical populations: an update. Urology 2002; 60 (Suppl 2B): 12–27.

    Article  PubMed  Google Scholar 

  14. Giuliano F et al. Switching from intracavernous prostaglandin E1 injections to oral sildenafil citrate in patients with erectile dysfunction: results of a multicenter European study. The Sildenafil Multicenter Study Group. J Urol 2000; 164: 708–711.

    Article  CAS  PubMed  Google Scholar 

  15. Althof SE et al. EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology 1999; 53: 793–799.

    Article  CAS  PubMed  Google Scholar 

  16. Rosen RC et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822–830.

    Article  CAS  PubMed  Google Scholar 

  17. Shabsigh R et al. Intracavernous alprostadil alfadex (EDEX/VIRIDAL) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra). Urology 2000; 55: 477–480.

    Article  CAS  PubMed  Google Scholar 

  18. Porst H . Erectile dysfunction: issues in current pharmacotherapy. In: Morales A (ed). Injectable Drugs: Advantages and Drawbacks. Martin Dunitz Ltd: London, 1998, pp 157–179.

    Google Scholar 

  19. Hatzichristou DG . Current treatment and future perspectives for erectile dysfunction. Int J Impot Res 1998; 10(Suppl 1): S3-13.

    PubMed  Google Scholar 

  20. Hatzichristou DG et al. Sildenafil versus intracavernous injection therapy: efficacy and preference in patients on intracavernous injection for more than 1 year. J Urol 2000; 164: 1197–1200.

    Article  CAS  PubMed  Google Scholar 

  21. Padma-Nathan H et al. A 4-year update on the safety of sildenafil citrate (Viagra®). Urology 2002; 60 (Suppl 2B): 67–90.

    Article  PubMed  Google Scholar 

  22. Althof SE, Stecher VJ, Tseng LJ . Evaluation of partner satisfaction with sildenafil citrate treatment in men with erectile dysfunction [abstract]. J Urol 2002; 167: 280.

    Article  Google Scholar 

  23. Lewis R et al. Patient and partner satisfaction with VIAGRA (sildenafil citrate) treatment as determined by the erectile dysfunction inventory of treatment satisfaction questionnaire. Urology 2001; 57: 960–965.

    Article  CAS  PubMed  Google Scholar 

  24. Marks LS et al. Treatment of erectile dysfunction with sildenafil. Urology 1999; 53: 19–24.

    Article  CAS  PubMed  Google Scholar 

  25. Jarow JP, Burnett AL, Geringer AM . Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J Urol 1999; 162: 722–725.

    Article  CAS  PubMed  Google Scholar 

  26. Rowland DL et al. Penile and finger sensory thresholds in young, aging, and diabetic males. Arch Sex Behav 1989; 18: 1–12.

    Article  CAS  PubMed  Google Scholar 

  27. Carrier S et al. Age decreases nitric oxide synthase-containing nerve fibers in the rat penis. J Urol 1997; 157: 1088–1092.

    Article  CAS  PubMed  Google Scholar 

  28. Garban H et al. Effect of aging on nitric oxide-mediated penile erection in rats. Am J Physiol 1995; 268: H467-H475.

    Google Scholar 

  29. Boolell M et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 47–52.

    CAS  PubMed  Google Scholar 

  30. Ismail M, Abbott L, Hirsch IH . Experience with intracavernous PGE-1 in the treatment of erectile dysfunction: dose considerations and efficacy. Int J Impot Res 1997; 9: 39–42.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The work was supported by Pfizer Inc.

Author information

Authors and Affiliations

  1. Department of Urology, Universita' Vita Salute San Raffaele, Milan, Italy

    F Montorsi

  2. Case Western Reserve University, Beachwood, Ohio, USA

    SE Althof

  3. International Pharmaceuticals Group, Pfizer Inc, New York, New York, USA

    M Sweeney

  4. Centro di Andrologia, Università di Pisa, Pisa, Italy

    F Menchini-Fabris

  5. Department of Urology, Università Cattolica, Rome, Italy

    F Sasso

  6. Department of Urology, CHU de Bicêtre, AP-HP, Le Kremlin Bicêtre, France

    F Giuliano

Authors
  1. F Montorsi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. SE Althof
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Sweeney
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F Menchini-Fabris
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F Sasso
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F Giuliano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F Montorsi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Montorsi, F., Althof, S., Sweeney, M. et al. Treatment satisfaction in patients with erectile dysfunction switching from prostaglandin E1 intracavernosal injection therapy to oral sildenafil citrate. Int J Impot Res 15, 444–449 (2003). https://doi.org/10.1038/sj.ijir.3901049

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901049

Keywords

This article is cited by

Search

Advanced search

Quick links